Metraipolis › archive › dc_fe7f6fe85f02

Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle Assessment — Europe PMC PMID:42092334

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42092334
DOI
10.1002/cpt.70301
License (as archived)
solo-consultazione
Archived
2026-11-02T15:37:45.236Z
SHA-256 of the archived text
df961e727c36d649030f9556913fcb6041a6350aaf1b3759cf274e0e723f9916
Stable URL of this page
https://metraipolis.com/documento/dc_fe7f6fe85f02

How to cite

Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle Assessment — Europe PMC PMID:42092334 — Europe PMC (en), https://europepmc.org/article/MED/42092334 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe7f6fe85f02 (Metraipolis archive dc_fe7f6fe85f02, sha256 df961e727c36d649030f9556913fcb6041a6350aaf1b3759cf274e0e723f9916)
BibTeX
@misc{dcfe7f6fe85f02,
  title = {Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle Assessment — Europe PMC PMID:42092334},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42092334},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe7f6fe85f02; sha256 df961e727c36d649030f9556913fcb6041a6350aaf1b3759cf274e0e723f9916},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42092334. Agents can read the archived copy with the MCP tool read_document.